300 related articles for article (PubMed ID: 29892935)
21. Assessing PDL-1 and PD-1 in Non-Small Cell Lung Cancer: A Novel Immunoscore Approach.
Paulsen EE; Kilvaer TK; Khanehkenari MR; Al-Saad S; Hald SM; Andersen S; Richardsen E; Ness N; Busund LT; Bremnes RM; Donnem T
Clin Lung Cancer; 2017 Mar; 18(2):220-233.e8. PubMed ID: 27816392
[TBL] [Abstract][Full Text] [Related]
22. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
23. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of serum matrix metalloproteinase-13 levels in patients with esophageal squamous cell carcinoma (ESCC).
Jiao XL; Chen D; Wang JG; Zhang KJ
Eur Rev Med Pharmacol Sci; 2014; 18(4):509-15. PubMed ID: 24610617
[TBL] [Abstract][Full Text] [Related]
25. Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity.
Hirahara S; Katsumata Y; Kawasumi H; Kawaguchi Y; Harigai M
Lupus; 2020 Jun; 29(7):686-696. PubMed ID: 32264742
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
27. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
[TBL] [Abstract][Full Text] [Related]
28. An expression of squamous cell carcinoma antigen 2 in peripheral blood within the different stages of esophageal carcinogenesis.
Yang YF; Li H; Xu XQ; Diao YT; Fang XQ; Wang Y; Zhao DL; Wu K; Li HQ
Dis Esophagus; 2008; 21(5):395-401. PubMed ID: 19125792
[TBL] [Abstract][Full Text] [Related]
29. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
30. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
31. A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma.
Steuer CE; Griffith CC; Nannapaneni S; Patel MR; Liu Y; Magliocca KR; El-Deiry MW; Cohen C; Owonikoko TK; Shin DM; Chen ZG; Saba NF
Mol Cancer Ther; 2018 Mar; 17(3):710-716. PubMed ID: 29440293
[TBL] [Abstract][Full Text] [Related]
32. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
[TBL] [Abstract][Full Text] [Related]
33. Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma.
Moratin J; Metzger K; Safaltin A; Herpel E; Hoffmann J; Freier K; Hess J; Horn D
Head Neck; 2019 Aug; 41(8):2484-2491. PubMed ID: 30821864
[TBL] [Abstract][Full Text] [Related]
34. Circulating levels of autoantibodies against L1-cell adhesion molecule as a potential diagnostic biomarker in esophageal squamous cell carcinoma.
Xu YW; Peng YH; Ran LQ; Zhai TT; Guo HP; Qiu SQ; Chen HL; Wu ZY; Li EM; Xie JJ
Clin Transl Oncol; 2017 Jul; 19(7):898-906. PubMed ID: 28181176
[TBL] [Abstract][Full Text] [Related]
35. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
[TBL] [Abstract][Full Text] [Related]
37. Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8⁺ T cells.
Leng C; Li Y; Qin J; Ma J; Liu X; Cui Y; Sun H; Wang Z; Hua X; Yu Y; Li H; Zhang J; Zheng Y; Wang W; Zhu J; Wang Q
Oncol Rep; 2016 Feb; 35(2):699-708. PubMed ID: 26718132
[TBL] [Abstract][Full Text] [Related]
38. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer.
Okuma Y; Hosomi Y; Nakahara Y; Watanabe K; Sagawa Y; Homma S
Lung Cancer; 2017 Feb; 104():1-6. PubMed ID: 28212990
[TBL] [Abstract][Full Text] [Related]
39. Serum sPD-1 and sPD-L1 as Biomarkers for Evaluating the Efficacy of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Patients.
Li Y; Cui X; Yang YJ; Chen QQ; Zhong L; Zhang T; Cai RL; Miao JY; Yu SC; Zhang F
Clin Breast Cancer; 2019 Oct; 19(5):326-332.e1. PubMed ID: 31176611
[TBL] [Abstract][Full Text] [Related]
40. Circulating CD14(+)HLA-DR(-/low) myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC.
Huang H; Zhang G; Li G; Ma H; Zhang X
Tumour Biol; 2015 Sep; 36(10):7987-96. PubMed ID: 25967454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]